Biomaterials Translational Forum 2021-08: Translational Research in Skeletal Tissue Regeneration

  • 29th August 2021, Sunday

    14:00-15:30 (London); 9:00-10:30 (New York); 21:00-22:30 (Beijing)

    Zooming info:


    Meeting ID: 826 657 0519
    Passcode: 718288
    Join by SIP: 8266570519@zoomcrc.com
    Join by H.323: (US West)

    Opening Remarks and Introduction (5 minutes) 

    Moderator: Prof. Bin Li
    Institute of Orthopaedics, Soochow University, China

    Musculoskeletal tissue repair: the role of mesenchymal stem cells and Hedgehog signaling (20 minutes )

    Prof. Ling Qin
    University of Pennsylvania, USA

    BMP2 Gene- and Cell-Activated Biomaterial Scaffold for Bone Tissue Engineering (20 minutes)

    Prof. Bing Wang
    University of Pittsburgh School of Medicine, USA

    Clinical translation of regenerative medicine -- a “three-step” translational strategy in GMU (20 minutes) 

    Prof. Zhiyong Zhang
    Guangzhou Medical University, China

    Discussion + Q&A (30 minutes): Panelists:  

    Prof. Gang Li
    The Chinese University of Hong Kong, China

    Prof. Jaimo Ahn
    The University of Michigan, USA 

    Prof. James T Triffitt
    University of Oxford, UK

    Organizing Committee (Alphabetically):
    Prof. Xu Cao
    Department of Orthopaedics, Johns Hopkins University, USA

    Prof. Xiaodong Guo
    Department of Orthopaedics, Wuhan Union Hospital, China

    Prof. Bin Li
    Institute of Orthopaedics, Soochow University, China

    Prof. Zengwu Shao
    Department of Orthopaedics, Wuhan Union Hospital, China

    Prof. Qian Wang
    University of South Carolina, USA

    Dr. Zhidao Xia
    Swansea University Medical School, Swansea, UK

    Prof. Weihua Xu
    Department of Orthopaedics, Wuhan Union Hospital, China

    Brief CV of Prof. Zhiyong Zhang

    Professor Zhiyong Zhang is the professor of Guangzhou Medical University(GMU) and the founding directors of the Translational Research Centre of Regenerative Medicine and 3D Printing Technologies of GMU, and the Biomedical Engineering Research Center of Guangdong Province. Previously, he was the adjunct professor of Fourth Military Medical University(2010-2012) and Professor /Group Leader of Shanghai Jiao Tong University and National Tissue Engineering Centre of China(2012-2016). He has been granted a number of talent scheme program awards including the National "One Thousand Young Talents"(China’s Recruitment Program of Global Experts)Award by the central government of China, “Eastern Scholar” Distinguished Professor award by Shanghai government and the “Outstanding Medical Academic Leader” award by Guangzhou government. 
    In the past 16 years, Prof. Zhang focused on the translational research of tissue engineering and regenerative medicine (TERM). He is pioneering in the use of allogenic mesenchymal stem cell source for TERM application, which has been approved by the Health Sciences Authority of Singapore for the first-in-man clinical trial. He have developed a TERM technology named Autologous Regenerative Factor Cocktail (ARFC), which has been used to successfully heal hundreds of patients including refractory wound, diabetic ulcer, tracheal stenosis, intrauterine adhesions and so on. He has filed more than 30 patents, published more than 70 academic papers in the international journals such as Advance Science, Bioactive Materials, Small, Biomaterials, and authored five bookchapters. He has given plenary, keynote, invited presentation in more than 40 international conferences and been granted 14 scientific awards including the Natural Science Award of Ministry of Education of China (the First Prize, 2014) and so on. His research effort led to the successful commercialization and clinical translation of a couple of TERM technologies, including ARFC technologies, bioreactor, stem cell culture media and so on. He served as committee member of Tissue Engineering Technical Committee in Standardization Administration of China (SAC, the counterpart of ISO) and the technical reviewing committee member for the Class III medical device for China’s National Medical Products Administration (NMPA, the counterpart of US FDA). Prof. Zhang has actively served in more than 20 international and national academic societies, including vice chair of Chinese Society of Tissue Engineering and Regenerative Medicine(since 2020), the SYIS Chair of TERMIS-AP (2009-2012). 

    Brief CV of Prof. Ling Qin

    Dr. Ling Qin is an Associate Professor of Orthopaedic Surgery and Co-Director of PCMD Histology Core at the University of Pennsylvania. She is also an Associate Editor of Journal of Orthopaedic Translation and a member of Editorial Board of Journal of Bone and Mineral Research. She became ASBMR fellow in 2018 and Fellow of International Orthopaedic Research (FIOR) in 2019. She is currently a standing member of NIH SBDD (Skeletal Biology Development & Disease) study section. To date, she has published more than 90 peer-reviewed research articles, reviewers, and book chapters in journals such as Sci Transl Med, J Clin Invest, PNAS, Elife, JBMR, Arthritis Rheumatol, Nature etc . The overall goal of her research is to combine studies on fundamental mechanisms of skeletal cell function with translational medicine approaches to treat skeletal diseases. Her group uses a combination of molecular, biochemical, imaging techniques, and animal models to investigate the molecular mechanisms by which hormones and growth factors regulate bone metabolism and skeletal development under normal and pathological conditions. In the past decade, she has made some groundbreaking discoveries that greatly advance our understanding of molecular regulation of bone and cartilage metabolism, stem cell biology, and skeletal development, and provided promising therapeutic tools for skeletal disorders, such as osteoporosis and osteoarthritis. 

    Brief CV of Prof. Bing Wang

    Dr. Bing Wang is an Associate Professor in the Vascular Medicine institute at the Department of Medicine, University of Pittsburgh School of Medicine. Dr. Wang has been engaging in recombinant adeno-associated viral (rAAV) vector-mediated gene transfer and associated techniques for the treatment of neuromuscular diseases for many years. He has laid the long-term research groundwork for the pathogenesis and treatment of Duchenne muscular dystrophy (DMD), such as rAAV-mediated mini-dystrophin gene replacement and anti-inflammation via NF-kappaB (NF-kB) inhibition. Recently, he published an International Patent Application for the 2nd generation of DMD gene therapy. His research group has also laid the groundwork for the proposed research by developing gene- and cell-based molecular techniques for in vivo and ex vivo gene transfer as well as biomaterial-mediated gene transfer for the tissue regeneration. Since 2008, Dr. Wang has authored/co-authored 55 peer-reviewed publications, 4 review papers, 6 book chapters, and has published 90 abstracts in national/international conferences. Dr. Wang also participates on the Editorials Boards of several professional journals grant review panels (DOD and NIH). He is currently serving as the Deputy Editor for Molecular Therapy Methods & Clinical Development, an official journal of the American Society of Gene & Cell Therapy (ASGCT). Dr. Wang is also served as the Chair of the Muscle Topic Committee for the 2018-2020 term, Orthopaedic Research Society.

    Brief CV of Prof. Gang Li

    Gang Li is a full professor in the Department of Orthopedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong. He received MBBS at the Fourth Military Medical University, Xian, China (1991) and D. Phil. at the University of Oxford School of Medicine, England, UK (1998). The focuses of his research are on biological mechanisms of distraction osteogenesis, stem cell biology, cell therapy applications in musculoskeletal tissue engineering.  He has published more than 260 peer-reviewed SCI articles with citations over 12,000 and H index 60 (Google scholar 07-2021); 15 book chapters, edited 3 books on tissue engineering, bone biology, distraction histogenesis and Ilizarov techniques.  He is a council member of Chinese Orthopaedic Research Society; Chinese ORS Representative to International Combined Orthopaedic Research Societies (ICORS); Member of International Committee, American Orthopaedic Research Society (ORS); Vice Chairman, Branch of Regenerative Biomaterials, Chinese Association of Materials; Member-at-Large (Global position), Tissue Engineering and Regenerative Medicine Society (TERMIS) Asia Pacific (AP); Chairman of ILLRS and ASAMI China Branch.  He is executive associate editor for Journal of Orthopaedic Translation (IF: 5.19); editor for Calcified Tissue International, Bone and Joint Research, Bone and Journal of Orthopaedic Research.  He holds honorary or visiting Professorship at many prestigious universities such as Monash University, Australia; South-East University Medical School, China; The Airforce Medical University, China; etc.  His work received serval awards including 1st Class Award in Science Advances, Ministry of Science and Technology, PR China; 1st Class Research Award in Science and Technology, Ministry of Education, China; 2nd Class Award in Medical Science and Technology, China Medical Association. He is elected as fellow of International Combined Orthopaedic Research Societies (FIORS) in 2016 and fellow of American Orthopaedic Research Society (FORS) in 2020.  

    Brief CV of Prof. James T, Triffitt

    James T Triffitt PhD is Emeritus Professor of Bone Metabolism, University of Oxford. He gained his Ph.D. at the University of Liverpool in 1964 for research on vitamin D effects on the skeleton. Thereafter he joined Dr W.F. Neuman, University of Rochester, New York studying the chemical dynamics of bone mineral before returning to the UK as MRC Scientific Staff. He moved to Oxford to join Maureen Owen in 1969 and together set up the MRC Bone Research Laboratory at the Nuffield Orthopaedic Centre. In 1979 he joined Professor Marshall Urist in Los Angeles for a two-year sabbatical working on bone morphogenesis and characterisation of BMP. Further work has concerned the characteristics of the stem cells of bone and the biological factors controlling bone formation and turnover in normal and pathological conditions. Other research includes tissue engineering skeletal tissues and investigating bone development and metabolism in common diseases such as osteoporosis and in rare diseases such as fibrodysplasia ossificans progressiva.

    Brief CV of Prof. Jaimo Ahn

    Jaimo Ahn MD PhD is a surgeon, educator, scientist, clinical investigator, innovator and Professor / Associate Chairman of Orthopaedic Surgery, Chief of Orthopaedic Trauma at the University of Michigan.  He maintains a busy academic surgical practice while actively engaged in national / international leadership activities including as lead author of “Injuries” in the Burden of Musculoskeletal Disease in the US, Chair of the Evidence Committee of the Orthopaedic Trauma Association (OTA), Board member of Clinical Orthopaedics & Related Research and American Physician Scientists Association, ad hoc Chair of NIH MOSS SBIR/STTR review and innovation activities including with Clementia (Palovaratene), Radius (Tymlos), Genentech (transgenic mice), Penn UpStart (Skelegen) and others. His collaborative research has been funded by the AO Foundation, OTA, NIH and published in NEJM, Lancet, JAMA journals, JCI, Science TM. He received his education / training at Stanford, University of Pennsylvania (formerly Advisory Dean), HSS/Cornell and University of Bern.

  • Pubdate: 2021-08-29    Viewed: 252